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Introduction 
Aortic stenosis (AS) is the most frequently acquired native val-
vular disease afflicting the elderly population in Western countries. 
The prevalence of degenerative AS among the elderly in Korea is 
also increasing as the Korean population is growing older. Symp-
tomatic severe AS is a lethal disease with a 2-year mortality rate of 
50%.1) Until recently, the only definitive treatment of severe AS has 
been surgical aortic valve replacement. However, accompanying co-
morbidities in elderly patients are associated with increased proce-
dure-related morbidity and mortality rates. About one third of pa-
tients with severe AS and older than 75 years are not referred to a 
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surgeon because of the high surgical risk associated with comor-
bidities.1)
The development of a catheter-based therapy for heart valve dise-
ase, in particular AS, is rapidly evolving. Transcatheter aortic valve 
implantation (TAVI) allows the aortic valve to be replaced without 
a sternotomy or cardiopulmonary support. In this case report, we de-
scribe the first Korean patient treated by TAVI using a CoreValve (Me-
dtronic, Minneapolis, MN, USA). 
Case 
An 84-year old male presented with shortness of breath during or-
dinary daily physical activity {New York Heart Association (NYHA) 
functional classification class III}. He also experienced syncope 2 
months prior to admission to our hospital and intermittent chest 
pain for 2 weeks leading up to admission. The patient had a past 
medical history of hypertension and chronic obstructive pulmonary 
disease. He had been diagnosed with moderate AS 4 years ago and 
followed up regularly with checkups in the outpatient clinic, and 
the patient had been prescribed irbesartan, amlodipine, hydrochlo-
rothiazide, atorvastatin. On admission his blood pressure and pulse 
rate were 150/70 mm Hg and 78/min, while body weight and height 
were 53 kg and 172 cm. The 12-lead electrocardiogram (ECG) on ad-
mission showed sinus rhythm with intermittent premature atrial 
complexes and findings suggestive of left ventricular hypertrophy 
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with strain signs on lateral leads. Cardiomegaly was noted on the 
chest X-ray. Transthoracic and transesophageal echocardiography 
revealed severe degenerative change of aortic valve with heavy cal-
cification (Fig. 1A). The aortic valve area was 0.76 cm2 with a mean 
systolic pressure gradient of 43 mm Hg and peak systolic pressure 
gradient of 79 mm Hg compatible with severe AS. The aorta diam-
eter was 21 mm at the aortic annulus, 32 mm at the sinus of val-
salva, and 36 mm in the ascending aorta. Left ventricular end dia-
stolic diameter was 52 mm and ejection fraction was 67%. There 
was mild pulmonary hypertension with an estimated right ventric-
ular systolic pressure of 38 mm Hg. Coronary angiography showed 
mild coronary artery disease with 50% stenosis at the mid left an-
terior descending segment. Computed tomography showed diffuse 
atherosclerotic change of aorta and both external iliac arteries with 
calcification. The minimal lumen diameter of right and left external 
iliac arteries was 6 mm and 7 mm, respectively. A pulmonary func-
tion test revealed mild obstructive airway disease. The logistic Eu-
roscore was calculated to be 36.1%. 
The TAVI procedure was performed under general anesthesia. The 
vascular access for CoreValve delivery catheter was obtained at the 
right common femoral artery (CFA) with standard percutaneous ac-
cess techniques. An 18 Fr introducer sheath was inserted through the 
right CFA after preparing percutaneous closure using two pre-load-
ed suture devices (Perclose Proglide, Abbott Vascular, Abbott Park, 
IL, USA). A pig tail catheter was inserted through the left CFA and 
positioned at the aortic root for the aortography during the proce-
dure. A temporary pacemaker was placed in the right ventricle via 
the left femoral vein. A 0.035 inch Amplatz Super Stiff wire (Boston 
Scientific, Natick, MA, USA) was inserted into the left ventricle th-
rough the 18 Fr sheath. Balloon dilation of the stenotic aortic valve 
was performed with a balloon (diameter 25 mm, length 40 mm, Z-
med, NuMED Inc., Hopkinton, NY, USA) under rapid pacing using a 
temporary pacemaker. Then, a 29 mm CoreValve was deployed at 
the aortic annulus under angiographic guidance (Fig. 2A). An imme-
Fig. 2. Fluoroscopic image during the implantation of the CoreValve (A) and post-procedural aortogram showing mild to moderate degree of aortic regur-
gitation (B).
A   B  
Fig. 1. Transthoracic echocardiogram with a parasternal long axis view of the aortic valve. Sclerocalcified stenotic aortic valve before TAVI (arrow, A) and im-
planted CoreValve after TAVI (arrowheads, B). AV: aortic valve, LA: left atrium, LV: left ventricle, RV: right ventricle, TAVI: transcatheter aortic valve implantation.
A   B  
AVA 0.76 cm2
MSPG 43 mm Hg
PSPG 79 mm Hg MSPG 7 mm Hg
PSPG 16 mm Hg
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diate post-procedural aortogram showed good position of the Co-
reValve with mild aortic regurgitation (Fig. 2B). Post-procedural tr-
ansthoracic echocardiography demonstrated a well-functioning 
CoreValve with a mean systolic pressure gradient of 7 mm Hg and 
peak systolic pressure gradient of 16 mm Hg (Fig. 1B). The right ven-
tricular systolic pressure decreased from 38 to 31 mm Hg, accom-
panied by moderate paravalvular aortic regurgitation (grade II/IV). 
After the procedure, the patient was observed in an intensive care 
unit for 72 hours with continuous ECG monitoring and temporary 
pacemaker back-up. No significant conduction abnormalities were 
observed except for transient nonspecific intraventricular conduc-
tion delay with incomplete left posterior hemifascicular block. The 
patient’s symptoms subsequently improved from NYHA class III to 
class I and was discharged from the hospital at day 8 post proce-
dure without any significant complication. A 3-month follow-up 
echocardiography revealed no significant interval change from the 
immediate post procedure echocardiographic findings. The patient 
remained free from any symptom or any major cardiovascular event 
for a total follow-up period of 6 months. 
Discussion
This is the first case of TAVI in Korea using a CoreValve. The cur-
rent indications for TAVI with CoreValve are the following: 1) symp-
tomatic, severe, and native aortic valve stenosis; 2) aortic annular 
dimensions between 18 and 27 mm and an ascending aortic diam-
eter of less than 45 mm; 3) age ≥80 years, surgical risk calculated 
with logistic EuroSCORE >20%,2)3) or age ≥65 years plus at least 1 
of the following risk factors: liver cirrhosis, respiratory failure, pul-
monary hypertension, previous cardiac surgery, right ventricular fail-
ure, hostile thorax (such as radiation, burns, previous thoracic pl-
eurodesis, or multiple thoracotomies), severe connective tissue 
disease, cachexia, and porcelain aorta. Exclusion criteria for TAVI 
comprised any of the following: 1) sepsis or active endocarditis, 2) 
hypersensitivity or contraindication to acetylsalicylic acid or clopi-
dogrel, 3) bleeding diathesis or coagulopathy, 4) recent myocardial 
infarction or cerebrovascular event, 5) the presence of left ventric-
ular or atrial thrombus, 6) previous aortic valve replacement, and 7) 
a secondary progressive disease with an expectancy of life of less 
than 1 year.4) The patient was 84 years old and had symptomatic se-
vere aortic valve stenosis complying with the indications for TAVI, 
and no exclusion criteria were present. 
Currently, two types of aortic valves are commercially available for 
percutaneous implantation, which are the balloon-expandable Ed-
wards-Sapien Transcatheter Heart Valve (Edwards, Lifesciences, Ir-
vine, CA, USA) and the self-expandable CoreValve.5) In the PART-
NER A trial, a randomized controlled trial comparing TAVI using Ed-
wards Sapien valve and surgical aortic valve replacement in high-
risk patients with severe AS, both treatments showed similar rates 
of survival and major stroke rate. However, all stroke and vascular 
complication rates were higher in the TAVI group, whereas major 
bleeding occurred more frequently in the surgery group.6) The PART-
NER B trial compared TAVI and medical treatment for clinical out-
comes in patients who could not undergo surgery. Although TAVI 
had major complications of stroke, vascular complications, and ma-
jor bleeding, but could lower all-cause mortality about 20% over 
standard medical treatment. A recent published Italian multicenter 
CoreValve registry study reported sustained clinical and functional 
cardiovascular benefits in high-risk patients with symptomatic AS 
up to a 3-year follow-up period.
A randomized clinical trial comparing TAVI using CoreValve and 
surgical treatment is still ongoing. Although there have been no 
randomized clinical trials comparing the two aortic valve systems, 
both systems appear to be similar in procedural success rates and 
clinical outcomes according to various registry data. In most recent 
studies, the procedural success and 30-day survival rates range over 
90%.8) Stroke is currently the major concern after TAVI, and so far 
stroke rates have been reported to be <5%.8)9) Generally, the Core-
Valve device is associated with less hemodynamic instability during 
deployment. Therefore, it is released gradually by adjusting its po-
sition and potentially retrievable if positioned incorrectly. By con-
trast, it is difficult to adjust the Sapien valve position during deploy-
ment. The risk of acute coronary obstruction by a displaced native 
valve leaflet may be lower with CoreValve. Significant atrioventric-
ular (AV) conduction system abnormalities requiring permanent 
pacemaker implantation have been reported after TAVI.10) As the 
stent containing the valve courses through the interventricular sep-
tum below the aortic valve, injury to the AV conduction system may 
be associated with new left bundle or complete heart block. The 
need for a permanent pacemaker appears to be higher with the Core-
Valve (range 9-36%) than with the Sapien valve (range 3-12%).9)10) 
This may be due to the fact that the stent of the CoreValve is longer 
than that of the Sapien valve and has more contact with the left 
ventricular outflow tract.9)10) In our patient, new nonspecific intra-
ventricular conduction delay with incomplete left posterior hemi-
fascicular block was noted after TAVI. However, it did not require 
pacemaker implantation. It is generally recommended to avoid low 
implantation of the valve and to monitor ECGs for at least 3 days 
after TAVI procedures. Although the device profile has been de-
creased to 18 Fr, the major vascular complication rate remains rela-
tively high (>10% in most instances).5)8) A careful estimation of the 
diameter, tortuosity and calcification of the iliofemoral arteries by 
angiography, computed tomography, or intravascular ultrasound 
in borderline case seems to be important in reducing such vascular 
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complications.11) In this case, the diameters of the iliac and common 
femoral arteries were larger than 6 mm and there was no problem 
with engaging the catheter through the iliofemoral artery to aorta. 
In the presence of inadequate transfemoral access routes, other 
vascular access such as transaxillar or direct aortic access needs to 
be considered. In contrast to the Sapien valve, the CoreValve is not 
available for transapical approach. In our patient, paravalvular leak-
age of a moderate degree was observed after the procedure. The 
long-term fate of this regurgitation is not well known. After the 
procedure, the patient’s symptoms were markedly improved from 
NYHA class III to class I. Durability and long-term safety of the cath-
eter-based aortic valves need to be clarified in further large-scale 
clinical trials with long-term follow-ups.9)12)13) 
In summary, this is the first case of severe aortic valve stenosis 
in Korea successfully treated by TAVI using a CoreValve. TAVI seems 
to be an effective alternative treatment in elderly patients at high 
risk for conventional surgery.8)12)
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